{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:08:21Z","timestamp":1790125701948,"version":"4.0.1"},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe the real\u2010world treatment persistence (defined as the continuation of medication for the prescribed treatment duration), demographics and clinical characteristics, and treatment patterns for patients prescribed erenumab for migraine prevention in Canada.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The effectiveness of prophylactic migraine treatments is often undermined by poor treatment persistence. In clinical trials, erenumab has demonstrated efficacy and tolerability as a preventive treatment, but less is known about the longer term treatment persistence with erenumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a real\u2010world retrospective cohort study where a descriptive analysis of secondary patient data was conducted. Enrollment and prescription data were extracted from a patient support program for a cohort of patients prescribed erenumab in Canada between September 2018 and December 2019 and analyzed for persistence, baseline demographics, clinical characteristics, and treatment patterns. Descriptive analyses and unadjusted Kaplan\u2013Meier (KM) curves were used to summarize the persistence and dose escalation\/de\u2010escalation at different timepoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data were analyzed for 14,282 patients. Median patient age was 47\u00a0years, 11,852 (83.0%) of patients were female, and 9443 (66.1%) had chronic migraine at treatment initiation. Based on KM methods, 71.0% of patients overall were persistent to erenumab 360\u00a0days after treatment initiation. Within 360\u00a0days of treatment initiation, it is estimated that 59.3% (KM\u2010derived) of patients who initiated erenumab at 70\u00a0mg escalated to 140\u00a0mg, and 4.4% (KM\u2010derived) of patients who initiated at 140\u00a0mg de\u2010escalated to 70\u00a0mg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The majority of patients prescribed erenumab remained persistent for at least a year after treatment initiation, and most patients initiated or escalated to a 140\u00a0mg dose. These results suggest that erenumab is well tolerated, and its uptake as a new class of prophylactic treatment for migraine in real\u2010world clinical practice is not likely to be undermined by poor persistence when coverage for erenumab is easily available.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14218","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T09:56:40Z","timestamp":1637575000000},"page":"78-88","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Real\u2010world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real\u2010world study"],"prefix":"10.1111","volume":"62","author":[{"given":"Jonathan","family":"Gladstone","sequence":"first","affiliation":[{"name":"Neurology Cleveland Clinic Canada  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Chhibber","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences University of Calgary  Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagdeep","family":"Minhas","sequence":"additional","affiliation":[{"name":"Real\u2010world Solutions IQVIA  Kirkland Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calum S.","family":"Neish","sequence":"additional","affiliation":[{"name":"Real\u2010world Solutions IQVIA  Kirkland Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Sarah","family":"Power","sequence":"additional","affiliation":[{"name":"Real\u2010world Solutions IQVIA  Kirkland Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Lan","sequence":"additional","affiliation":[{"name":"Real\u2010world Solutions IQVIA  Kirkland Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5587-4360","authenticated-orcid":false,"given":"Driss","family":"Rochdi","sequence":"additional","affiliation":[{"name":"Neuroscience Novartis Pharmaceuticals Canada Inc.  Dorval Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Lanthier\u2010Martel","sequence":"additional","affiliation":[{"name":"Neuroscience Novartis Pharmaceuticals Canada Inc.  Dorval Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Bastien","sequence":"additional","affiliation":[{"name":"Neuroscience Novartis Pharmaceuticals Canada Inc.  Dorval Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"issue":"4","key":"e_1_2_10_2_1","first-page":"S3","article-title":"Migraine prevalence, diagnosis, and disability","volume":"34","author":"Becker WJ","year":"2007","journal-title":"Can J Neurol Sci"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1017\/s0317167100010738"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/23.5.1020"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100041950"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(18)30322\u20103"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1017\/s0317167100010453"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_10_9_1","first-page":"S1","article-title":"Canadian Headache Society guideline for migraine prophylaxis","volume":"39","author":"Pringsheim T","year":"2012","journal-title":"Can J Neurol Sci"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468\u20102982.2005.01077.x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2014.20.1.22"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416678382"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010019\u201001069\u20101"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(17)30083\u20102"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"e_1_2_10_17_1","volume-title":"Aimovig (erenumab)","author":"Novartis Pharmaceuticals Canada Inc","year":"2019"},{"issue":"5","key":"e_1_2_10_18_1","first-page":"380","article-title":"Survival analysis","volume":"2","author":"Fink SA","year":"2006","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(18)30478\u20101"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12055"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420946725"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13951"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194\u2010020\u201001127\u20100"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14218","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.14218","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:46:20Z","timestamp":1762076780000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1111\/head.14218"],"URL":"https:\/\/doi.org\/10.1111\/head.14218","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,22]]},"assertion":[{"value":"2021-04-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}